Purple Biotech Q4 2023 EPS Loss Of $(0.33) Up From $(0.44) YoY. Cash And Cash Equivalents, Short- And Long-term Deposits Of $31.7M, Providing Cash Runway Into Second Half Of 2024
Purple Biotech Reports An Operating Loss Of $6.6M, Up 40.4% Y/Y
Stocks That Hit 52-Week Lows On Thursday
During Thursday's trading, 138 companies set new 52-week lows.
Purple Biotech Q3 EPS $(0.27)
Purple Biotech (NASDAQ:PPBT) reported quarterly losses of $(0.27) per share.
Purple Biotech’s Assets Are First In Class For Solid Tumor Treatment, Analyst Says
HC Wainwright initiated coverage on Purple Biotech (NASDAQ:PPBT) with a Buy rating and a price target of $7. The company is working…
HC Wainwright & Co. Initiates Coverage On Purple Biotech with Buy Rating, Announces Price Target of $7
HC Wainwright & Co. analyst Emily Bodnar initiates coverage on Purple Biotech (NASDAQ:PPBT) with a Buy rating and announces Price Target of $7.
Chardan Capital Initiates Coverage On Purple Biotech with Buy Rating, Announces Price Target of $11
Chardan Capital analyst Matthew Barcus initiates coverage on Purple Biotech (NASDAQ:PPBT) with a Buy rating and announces Price Target of $11.